Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ATF1 | P18846 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | PDE6D | O43924 | 1/20 | 0.42 |
| ▸ | PDE6A | P16499 | 1/20 | 0.42 |
| ▸ | PDE6G | P18545 | 1/20 | 0.42 |
| ▸ | PDE6B | P35913 | 1/20 | 0.42 |
| ▸ | PDE6C | P51160 | 1/20 | 0.42 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926728 | 0.87 | KDM4E (0.45) | KMT2AMEN1ATF1NFKB1KDM4E | |
| SCHEMBL6083583 | 0.85 | KMT2A (0.55) | KMT2AMEN1KDM4EL3MBTL1MAPT | |
| SCHEMBL12794277 | 0.85 | KMT2A (0.55) | KMT2AMEN1KDM4EL3MBTL1THRB | |
| SCHEMBL18285386 | 0.83 | KMT2A (0.53) | KMT2AMEN1KDM4ETHRBMAPT | |
| SCHEMBL539020 | 0.82 | KMT2A (0.56) | KMT2AMEN1KDM4EMAPTUSP2 | |
| SCHEMBL21591834 | 0.81 | KMT2A (0.50) | KMT2AMEN1KDM4EPDE5AL3MBTL1 | |
| SCHEMBL649687 | 0.80 | PDE5A (0.60) | KMT2AMEN1KDM4EPDE5AL3MBTL1 | |
| SCHEMBL2719292 | 0.78 | KMT2A (0.68) | KMT2AMEN1MAPTUSP2TP53 | |
| SCHEMBL429137 | 0.78 | PDE5A (0.60) | KMT2AMEN1ATF1NFKB1KDM4E | |
| SCHEMBL1285850 | 0.77 | KMT2A (0.49) | KMT2AMEN1KDM4EPDE5AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598159-B2 | Therapeutic pyrazoloquinoline derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-12-03 | — | — | US | disclosed |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-7872002-B2 | Therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872002-B2 | Therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872002-B2 | Therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| CN-101742908-A | therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS INC | 2010-06-16 | — | — | CN | disclosed |
| EP-2166852-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | Helicon Therapeutics, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008154438-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | GABRA5, GABRB1, GABRB2 | KMT2A 2970/4885MEN1 3172/4885ATF1 1809/4885 |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | GABRA5, GABRB1, GABRB2 | KMT2A 2970/4885MEN1 3172/4885ATF1 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.